Compounded GLP-1 recall stays small but pointed. Apothecary Pharma of Cary, North Carolina is recalling 22 vials of compounded tirzepatide injection (18 mg/mL) and one vial of NAD+ injection because sterility cannot be assured, according to the FDA enforcement report of October 14. The FDA classified the recall as Class II on October 8, meaning serious harm is considered unlikely, and no illnesses were reported. The pharmacy initiated the recall on September 24; an FDA warning letter in December 2025 had cited deficiencies in its sterile production practices, though the agency has not linked the two. Brand-name Mounjaro and Zepbound are not affected. Source: FDA enforcement report via BioPharma Dive and ConsumerAffairs, October 2026.
State officials compare notes on Medicaid work requirements. State Medicaid officials met this week to swap implementation notes as they scramble to build systems for the new federal work requirements, STAT reported on October 23. The requirements are the largest administrative change to the program in years, and states are working to different timelines with different verification technology, which is where coverage losses for eligible people usually occur. Source: STAT, October 23, 2026.
Nutrition experts press for the ultra-processed food definition. Nutrition experts are pressing the White House to release its long-awaited definition of ultra-processed foods, STAT reported on October 22, arguing that without a definition the administration’s food policy has no enforceable object. The definition, a Make America Healthy Again priority, would shape any future labelling, procurement or guidance that turns on the category. The push lands the same week the movement’s best-known White House adviser, Calley Means, resigned (see the October 22 story). Source: STAT, October 22, 2026.
Industry weighs evidence standards for generative AI devices. Healthcare industry commenters are weighing in on what evidence standards should apply to generative AI medical devices, Endpoints News reported on October 22, as regulators work out how to evaluate products whose outputs change as models update. The fight is over whether premarket evidence should include prospective clinical data or whether real-world performance monitoring can carry more of the load. Source: Endpoints News, October 22, 2026.
Sanofi German site and radioisotope deals in the Endpoints digest. Endpoints News’s October 22 digest carried Sanofi opening a new German site and radioisotope supply deals from NorthStar and Telix, without figures in the accessible text, so the items are logged here rather than written up: radioisotope supply remains a standing constraint on the radiopharmaceutical pipeline, and any capacity addition is worth tracking when terms are published. Source: Endpoints News, October 22, 2026.
Quest Diagnostics pauses a lab system after a cybersecurity event. Health IT reporting on October 23 said Quest Diagnostics paused access to its Quanum lab system, used by some customers to place orders and receive results, after a cybersecurity event, while direct EHR interfaces were unaffected. The item is logged here as a developing operational story; Quest had not published terms or a restoration timeline in the reporting available. Source: HIStalk, October 23, 2026.